UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

~~March~~October 1916, 2019 Date of Report (Date of earliest event reported)

GALA PHARMACEUTICAL INC.

(Exact name of registrant as specified in its charter)

NEVADA	000-52044	42-1771014
(State or other jurisdiction of	(Commission File	(IRS Employer Identification No.)
incorporation)	Number)
18881 Von Karman Avenue, Suite 1440, Irvine, California		92612
18881 Von Karman Ave., suite 1440		92612
(Address of principal executive offices)		(Zip Code)

(~~949~~714) ~~851~~612-~~9261 Registrant's telephone number, including area code~~4725

Registrant's telephone number, including area code

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K fifiling ~~ling~~ is intended to simultaneously satisfy the fifiling ~~ling~~ obligation of the registrant under any of the following provisions ~~(see General Instruction A.2. below)~~:

~~[_]~~☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

~~[_]~~☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

~~[_]~~☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

~~[_]~~☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
N/A	N/A	N/A

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ~~[_]~~ ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised ~~financial~~ financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ~~[_]~~ ☐

ITEM 82.0104. ~~OTHER~~TRIGGERING EVENTS THAT ACCELERATE OR INCREASE A DIRECT FINANCIAL OBLIGATION

~~Audit~~On ~~update:~~October ~~Gala~~4, ~~Pharmaceutical Inc.~~2019, Mohan ~~(the~~Singh ~~“Company”)~~Makkar isfiled ~~unable~~a toUnlawful ~~file,~~Detainer ~~without unreasonable effort~~ and ~~expense,~~Eviction ~~its~~Notice ~~Annual~~against ~~Report~~Gala onPharmaceutical ~~Form 10-K for the fiscal year ended November 30~~California, ~~2018~~Inc. ~~(the~~pursuant ~~“2018~~to ~~Form~~a ~~10-K”)~~Lease ~~because the Company has experienced unexpected delays in~~agreement ~~its~~entered ~~completion~~into ofon ~~the~~May ~~audit of its financial statements for the fiscal year ended November 30~~1, 2018,. ~~due~~The toamount ~~the~~owed ~~complexity~~was ~~and significant scope of work required to account for certain transactions and related tax accounting~~$37,440. AsThe aparties ~~result,~~are ~~the~~in ~~Company~~process ~~requires additional time to finalize its financial statements to be filed as part~~ of ~~the~~finalizing ~~2018~~a ~~Form~~settlement ~~10-K, and plans~~ to ~~file~~this ~~its Form 2018 10-K within the next 14 days~~action.

~~Testing License~~ITEM ~~Update: Gala Pharmaceutical Inc~~5. ~~had submitted an application to the city of Long Beach for cannabis testing laboratory license~~02. ~~While~~DEPARTURE ~~Gala~~OF ~~was~~DIRECTORS ~~pursuing~~OR toPRINCIPAL ~~receive~~OFFICERS; ~~its~~ELECTION ~~building~~OF ~~permit~~DIRECTORS; toAPPOINTMENT ~~build~~OF aPRINCIPAL cannabis testing laboratory, the city advised Gala to apply for State application for licensing. Gala applied for State license in and received state license on December 10, 2018. Soon after receiving the license the state official contacted Gala for a facility tour. Such official had the impression that that the lab was already built. However the lab was not build because Gala was still waiting on city of Long Beach to issue build out permits. The state officials requested to surrender the state license voluntarily as a formality and re-apply for permanent state license once the labs is completely build out. Since then Gala received the building permit from the City of Long Beach and has started the build-out which is scheduled to be completed by May 19, 2019. Gala intends to resubmit the state application shortly.OFFICERS

~~Signatures~~Mr. Maqsood Rehman resigned as an officer and director with the Company and all affiliates effective as of September 9, 2019. The resignation was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

~~Pursuant~~Mr. toReinier ~~the~~Hoogenraad ~~requirements~~resigned as a director ofwith the ~~Securities~~Company ~~Exchange~~effective ~~Act~~as of ~~1934~~October 16, ~~the~~2019. ~~Registrant~~The ~~has~~resignation ~~duly~~was ~~caused~~not ~~this~~the ~~report~~result toof beany ~~signed~~disagreement with the Company on ~~its~~any matter ~~behalf~~relating byto the ~~undersigned thereunto~~Company’s ~~duly~~operations, ~~authorized~~policies or practices.

Date: March 19, 2019	By:	/s/ Maqsood Rehman
		Maqsood Rehman
	Title:	Chief Executive Officer

On October 16, 2019, Ms. Romina Martinez was appointed as a member of the Company’s Board of Directors as well as CEO, President, CFO and Secretary.

2Her biography is set forth below:

Romina Martinez, for the past two years has worked with an international company in the internet advertising and social media industry. Prior to that, Ms. Martinez worked in the legal field for over seven years with a focus on international business operations. She is highly knowledgeable in the creation of new corporations, licensing, contracts, and the issues that arise therefrom. Ms. Martinez has worked closely with various companies in the legal medicinal and recreational cannabis industry including CBD and industrial hemp markets over the past nine years. She is bringing with her a distribution platform that leverages on her knowledge gained in the internet marketing industry. Ms. Martinez also previously served as a director for Gala from February 10, 2017 to September 26, 2018

Mr. Peter Um resigned as the chief scientific officer with the Company effective as of August 28, 2019. The resignation was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

Item 9.01.

Financial Statements, Pro Forma Financial Information and Exhibits.

(b)

Exhibit No.	Exhibit
17.1	Resignation of Maqsood Rehman
17.2	Resignation of Reinier Hoogenraad

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

/s/ Romina Martinez	Date:	October 18, 2019
_________________		_____________________________

Officer, Director

Filing Compare · Gala Pharmaceutical Inc.